Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven aggressive T-cell Non-Hodgkin's lymphoma (NHL)~2. Age 18 -75 years~3. Ann Arbor stage II, III and IV (Appendix A)~4. Relapsed or refractory cases to previous treatments~5. Performance status (ECOG) ≤ 2 (Appendix B)~6. At least one or more bidimensionally measurable lesion(s)~   * ≥ 2 cm by conventional CT~  * ≥ 1 cm by spiral CT~  * skin lesion (photographs should be taken) ≥ 2 cm~  * measurable lesion by physical examination ≥ 2 cm~7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2DECHO without clinically significant abnormalities~8. Adequate renal function: serum creatinine level \< 2 mg/dL (177 μmol/L)~9. Adequate liver functions: Transaminase (AST/ALT) \< 3 X upper normal value (or \< 5 x ULN in the presence of DLBCL involvement of the liver), Bilirubin \< 2 X upper normal value (or \< 5 x ULN in the presence of PTCL involvement of the liver)~10. Adequate BM functions: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma~11. A negative serum or urine pregnancy test prior to treatment must be available both for pre-menopausal women and for women who are \< 1years after the onset of menopause.~12. Informed consent~Exclusion Criteria:~1. ALK-positive anaplastic large cell lymphoma and Sezary syndrome.~2. CNS or testis involvement.~3. Previously treated with the regimen containing bendamustine or platinum agents.~4. Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri~5. Pregnant or lactating women, women of childbearing potential not employing adequate contraception~6. Other serious illness or medical conditions~7. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry~8. History of significant neurologic or psychiatric disorders including dementia or seizures~9. Active uncontrolled infection (viral, bacterial or fungal infection)~10. Other serious medical illnesses~11. Known hypersensitivity to any of the study drugs or its ingredients~12. Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BCD chemotherapy (Type: OTHER): All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete